In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Next generation sequencing (NGS), or massively parallel sequencing, refers to high-throughput methods for DNA sequencing that are not Sanger-based, based on clonally amplified DNA templates or single DNA molecules rather than electrophoretic separation of chain-termination products produced in individual sequencing reactions. GlobalData uses proprietary data and analytics to provide a comprehensive report on the next generation sequencing devices market, including market shares of different players within Italy. Buy the latest report here.

Smarter leaders trust GlobalData


Premium Insights Italy Next Generation Sequencing Market Share

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

In 2022, GlobalData’s Market Model methodology determined that the leading player in the next generation sequencing market in Italy was Illumina followed by Thermo Fisher Scientific, Qiagen, Agilent Technologies, New England Biolabs, F. Hoffmann-La Roche and Amoy Diagnostics.

NGS technology has largely superseded Sanger sequencing in academic or genome research and is increasingly being applied in clinical practice. The technique is highly scalable and typically involves fragmenting the genome and then randomly sampling for and sequencing these fragments. NGS can be performed on formalin-fixed and paraffin-embedded (FFPE) and freshly collected tissue specimens and on fine-needle aspiration samples and small biopsy specimens. NGS encompasses a number of different sequencing platforms; whole-genome sequencing, exome sequencing, transcriptome sequencing (mRNA sequencing), and targeted sequencing of multigene panels, all of which simultaneously sequence millions of DNA fragments and later reply on bioinformatics analysis to map these reads to a human reference genome. In this model, GlobalData has considered pyrosequencing reagents to be NGS tests.

Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the next generation sequencing devices market within Italy was expected to be over $1m in 2022.

For the latest complete market share analysis of next generation sequencing device market in Italy, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.